May 24

** All times are in Eastern US time **

11:00 am - 11:10 am
  • Introduction & Welcome

    • National Cancer Institute Director - Norman Sharpless
    • RAS Scientific Consultant - Frank McCormick
11:10 am - 11:40 am
  • Keynote Speaker:

    • Charles Swanton | Francis Crick Institute
    • “Cancer Evolution, Immune Evasion and Metastasis”
11:40 am - 2:00 pm
  • RAS Biology (Session Chair: Frank McCormick)

    11:40 am: Mariano Barbacid | CNIO - Spanish National Cancer Research Center
    “Targeting KRAS Cancer: Target Inhibition vs Target Ablation”
    12:10 pm: Andy Aguirre | Dana-Farber Cancer Institute, Harvard Medical School
    “Acquired Resistance to KRAS G12C Inhibition”
    12:40 pm: Pablo Rodriguez-Viciana | University College London
    “The SHOC2 Phosphatase Complex: A Node for Selective Inhibition of the ERK Pathway in RAS-driven Cancers”
    1:10 pm: Marie Evangelista | Genentech
    “CLAMPing Down on KRAS: Conformation Locking Antibodies to Drug KRAS-driven Tumors and to Investigate Drug Resistant Mechanisms”
    1:40 pm: Short Talk: Lauren Adams | Northwestern University
    “Characterization of the KRAS Proteoform Landscape in Colorectal Cancer by Top-Down Proteomics”
2:00 pm - 3:00 pm
3:00 pm - 5:40 pm
  • Structure (Session Chair: Dwight Nissley)

    3:00 pm: Dhirendra Simanshu | Frederick National Laboratory for Cancer Research
    “Novel Structural Insights into RAS-effector Interactions”
    3:30 pm: Debbie Morrison | National Cancer Institute
    “Structural Insights on How RAS Binding Mediates the B-RAF Monomer to Dimer Transition”
    4:00 pm: Michael Eck | Dana-Farber Cancer Institute, Harvard Medical School
    “Insights into RAS/MAP Kinase Pathway Regulation and Pharmacology from cryo-EM Structures of BRAF/MEK/14-3-3 Complexes”
    4:30 pm: Chris Marshall | Princess Margaret Cancer Center
    “Calmodulin Regulates KRAS4b Localization Through Sequestration of the Farnesyl Moiety”
    5:00 pm: Short Talk: Jana Ognjenovic | Frederick National Laboratory for Cancer Research
    “Cryo-EM Structure and Conformational Dynamics of Human Neurofibromin”
    5:20 pm: Short Talk: Dr. Timothy Wendorff | Genentech
    “Oncogenic BRAF Mutations Overcome Negative Regulation of RAF Activity by ATP and Promote Dimerization to Activate MAPK Pathway Signaling”

May 25

11:00 am - 1:40 pm
  • RASopathies (Session Chair: Dom Esposito)

    11:00 am: Kate Rauen | University of California, Davis
    “Modeling RASopathies: Skeletal Myopathy in Costello Syndrome”
    11:30 am: Brigitte Widemann / Marielle Yohe | National Cancer Institute
    Widemann: “Neurofibromatosis type I”
    Yohe: “Natural History Study of RASopathies”
    12:00 pm: Maria Kontaridis | Beth Israel Deaconess Medical Cener, Harvard Medical School
    “Causal Mechanisms for RAF1-mediated Cardiac Hypertrophy in RASopathies”
    12:30 pm: Pau Castel | University of California, San Francisco
    “Role of the RAS GTPase RIT1 in RASopathies and Cancer”
    1:00 pm: Short Talk: Antonio Cuevas Navarro | University of California, San Francisco
    “Mutant RIT1 Compromises Mitotic Fidelity Through Suppression of the Spindle Assembly Checkpoint”
    1:20 pm: Short Talk: Russell Spencer-Smith | National Cancer Institute
    “Germline RASopathy Mutations Provide Functional Insights into the RAF Cysteine-Rich Domain (CRD)”
1:40 pm - 3:00 pm
3:00 pm - 6:10 pm
  • Therapeutics (Session Chair: Caroline DeHart)

    3:00 pm: David Turner | Frederick National Laboratory for Cancer Research
    “Mapping the Surface of Mars: Identification of Novel Binding Pockets in KRAS”
    3:30 pm: Craig Crews | Yale University
    “PROTAC-mediated K-RAS Degradation”
    4:00 pm: Rusty Lipford | Amgen
    “Sotorasib: CodeBreaK 100 Registrational Phase 2 Results and Pre-clinical Update”
    4:30 pm: Kevan Shokat | University of California, San Francisco
    “Identification of Drug Binding Pockets for Distinct Nucleotide States of Oncogenic K-RAS Mutants”
    5:00 pm: Karen Cichowski | Brigham and Women's Hospital, Harvard Medical School
    “Developing Combinatorial Strategies for RAS-driven Cancers”
    5:30 pm: Short Talk: Xosé R. Bustelo | University of Salamanca
    “RRAS2 Mutations Act as Fully Autonomous Cancer Drivers in a Variety of Tumor Types”
    5:50 pm: Short Talk: Luca Gerosa | Harvard Medical School
    “Pulsatile Reactivation of MAPK Signaling Enables Persistence of Drug-adapted BRAF-mutant Melanoma Cells”

May 26

11:00 am - 1:40 pm
  • Therapeutics II (Session Chair: Tommy Turbyville)

    11:00 am: Mollie Leoni | Kura Oncology, Inc.
    “Investigating Single Agent and Combination Tipifarnib Strategies to Treat HRAS Dependent Head and Neck Squamous Cell Carcinoma”
    11:30 am: Darryl McConnell | Boehringer Ingelheim
    “Inhibitors and PROTACs for all KRAS Mutants”
    12:00 pm: Piro Lito | Memorial Sloan Kettering Cancer Center
    “Regulators of the KRAS Nucleotide Cycle and Susceptibility to Emerging Therapeutics”
    12:30 pm: Bob Nichols | Revolution Medicines, Inc.
    “RMC-6291: Biological Features of Targeting KRASG12C(ON) and Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumor”
    1:00 pm: Short Talk: Oleksii Rukhlenko | University College Dublin
    “Targeting Oncogenic RAS Using Next-Generation Modelling”
    1:20 pm: Short Talk: Matthias Drosten | CNIO - Spanish National Cancer Research Center
    “KRAS4A Induces Metastatic Lung Adenocarcinomas in vivo in the Absence of the KRAS4B Isoform “
1:40 pm - 3:00 pm
3:00 pm - 5:30 pm
  • RAS Biology II (Session Chair: Andy Stephen)

    3:00 pm: Dave Tuveson | Cold Spring Harbor Laboratory
    “Models Identify New RAS Effectors in Pancreatic Cancer”
    3:30 pm: Channing Der | University of North Carolina
    “Targeting KRAS Effector Signaling for the Treatment of Pancreatic Cancer”
    4:00 pm: Bill Hahn | Dana-Farber Cancer Institute, Harvard Medical School
    “Systematic Approaches to Understand KRAS Function”
    4:30 pm: Arvin Dar | Icahn School of Medicine at Mount Sinai
    “Structural Basis for the Action of Clinical MEK Inhibitors at KSR-MEK-RAF”
    5:00 pm: Christian Burd | The Ohio State University
    “Unravelling the Mystery of NRAS Mutational Selectivity in Melanoma”

An asynchronous week-long poster session will be available to all registered participants for the full week: May 24th – June 7th.